Posted on
November 25, 2021

GIP-dependent primary bilateral macronodular adrenal hyperplasia with Cushing’s syndrome is caused by aberrant expression of the GIP receptor in adrenal lesions. This multicentre, retrospective, cohort study at endocrine hospitals and university hospitals in France, Canada, Italy, Greece, Belgium, and the Netherlands aims to identify the underlying genetic driver event.

Posted on
July 13, 2021

Although bilateral adrenalectomy has been extensively used to treat patients with overt CS, studies have shown the benefit of unilateral adrenalectomy for the management of some tumor subtypes. This Publication Highlight examines the role of unilateral adrenalectomy in the management of primary bilateral macronodular adrenocortical hyperplasia, a rare form of pituitary ACTH-independent Cushing’s syndrome.

Posted on
April 28, 2021

Steroidogenesis inhibitors are recommended when surgery has failed or is otherwise inappropriate, when it has been refused by the patient, or while waiting for maximal radiation therapy to take effect. Several factors must be considered when initiating and maintaining steroidogenesis inhibition – this summary offers an example of the ‘titrate to normalization’ approach to therapy and compares the latter with ‘block and replace’, covering patient selection, ‘how’, monitoring and side effects.

Posted on
February 17, 2021

Patients with active Cushing’s syndrome may be immunocompromised, and so require strict adherence to barrier methods to prevent infection with COVID-19. Clinical practice guidelines lay out the key principles of care of these patients during the pandemic, including algorithms for investigations and management of the syndrome.